Skip to main content
. 2016 Mar 3;2(4):e69. doi: 10.1097/TXD.0000000000000579

FIGURE 1.

FIGURE 1

Disposition of the study population. *Received ≥1 dose of assigned therapy. Remained on assigned therapy through 24 months after transplantation for the primary end point. d/c, discontinued; FSGS, focal segmental glomerulosclerosis; MPGN, membranoproliferative glomerulonephritis.